CEFADROXIL

SynDRA canonical compound SYN0016060 — structure-anchored drug synonym record

Clinical phase	Launched
Approval status	Approved · Rx/OTC
Primary target(s)	SLC22A8
Mechanism of action	Bacterial cell wall synthesis inhibitor
Indication	pharyngitis \| skin infections \| tonsillitis \| urinary tract infections \| urinary tract infections, skin infections, tonsillitis, pharyngitis
Disease area	infectious disease \| infectious disease \| infectious disease, otolaryngology \| otolaryngology \| otolaryngology

All known targets

cefadrox
cephadroxil
cefadroxil hemihydrate
Cefadroxil/cefadroxil hemihydrate
Cefadroxilo
Cefadroxil monohydrate
Anhydrous cefadroxil
Cefadroxil (as monohydrate)
Cefadroxil anhydrous
Cefadroxil hydrate
Duracef
BL-S578
MJF-11567-3
NSC-756664
Baxan
Cefadrops
Cefatabs
Duricef
Ultracef
CDX
Cefadroxilum
Cephadroxil
Sumacef
S-578
BL-S 578
Cefadroxil (JP15)
Cefadroxilo [INN-Spanish]
Cefadroxilum [INN-Latin]
Curisafe (TN)
D-Cefadroxil
Sumacef (TN)
(6R,7R)-7-((R)-2-Amino-2-(p-hydroxyphenyl)acetamido)-3-methyl-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
(6R,7R)-7-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
(6R,7R)-7-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3-methyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
7beta-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,4-didehydrocepham-4-carboxylic acid
Q525PA8JJB
NSC 756664
MJF 11567-3